Regulatory T Cells with Additional COX-2 Expression Are Independent Negative Prognosticators for Vulvar Cancer Patients.
COX-2
M2-polarized macrophages
regulatory T cells
tumor-infiltrating lymphocytes
vulvar cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Apr 2022
22 Apr 2022
Historique:
received:
01
02
2022
revised:
12
04
2022
accepted:
21
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Vulvar cancer incidence numbers have been steadily rising over the past decades. In particular, the number of young patients with vulvar cancer has recently increased. Therefore, the need to identify new prognostic factors and, in addition, therapeutic options for vulvar carcinoma is more apparent. The aim of this study was to analyze the influx of COX-2 positive tumor-infiltrating lymphocytes and monocytes and their influence on prognosis. Using subtyping by immunofluorescence, the majority of COX-2 expressing immune cells were identified as FOXP3-positive regulatory T cells. In addition, peri- and intra-tumoral macrophages in the same tumor tissue were detected simultaneously as M2-polarized macrophages. COX-2 positive immune cells were independent negative prognostic markers in long-term overall survival of patients with vulvar cancer. These results show an influence of immune cell infiltration for vulvar carcinoma patients. Immune cell infiltration and immune checkpoint expression may, therefore, become interesting targets for further research on new vulvar cancer treatment strategies.
Identifiants
pubmed: 35563052
pii: ijms23094662
doi: 10.3390/ijms23094662
pmc: PMC9099805
pii:
doi:
Substances chimiques
Cyclooxygenase 2
EC 1.14.99.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
Science. 2003 Feb 14;299(5609):1057-61
pubmed: 12522256
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842422
Histopathology. 2013 Jan;62(1):161-75
pubmed: 23190170
Diagnostics (Basel). 2021 Mar 10;11(3):
pubmed: 33802010
Cell. 2000 May 26;101(5):455-8
pubmed: 10850488
J Surg Res. 2011 May 15;167(2):e211-9
pubmed: 19765725
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
Gynecol Oncol. 2019 Sep;154(3):565-570
pubmed: 31227222
Am J Physiol. 1992 Jul;263(1 Pt 2):F97-102
pubmed: 1636747
Gynecol Oncol. 2012 Jul;126(1):87-92
pubmed: 22516660
J Cancer Surviv. 2016 Apr;10(2):261-70
pubmed: 26245979
Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
Clin Cancer Res. 2001 May;7(5):1410-8
pubmed: 11350912
Br J Cancer. 2004 Jan 26;90(2):423-9
pubmed: 14735188
Nat Immunol. 2003 Apr;4(4):337-42
pubmed: 12612581
Front Oncol. 2021 Jun 10;11:686792
pubmed: 34178680
Cell Metab. 2007 Aug;6(2):137-43
pubmed: 17681149
FASEB J. 1993 Aug;7(11):1045-51
pubmed: 8370474
Gut. 2006 Jan;55(1):115-22
pubmed: 16118353
Cancer Res. 1995 Sep 1;55(17):3785-9
pubmed: 7641194
Eur J Cancer Prev. 1995 Dec;4(6):491-5
pubmed: 8580785
Curr Med Chem. 2019;26(18):3225-3241
pubmed: 29756563
Cancer Manag Res. 2017 Nov 30;9:741-750
pubmed: 29238224
Cancer Res. 2001 Jun 15;61(12):4766-72
pubmed: 11406550
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
J Exp Med. 1989 Jun 1;169(6):2233-8
pubmed: 2471777
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
J Lab Clin Med. 1996 Sep;128(3):242-5
pubmed: 8783630
Cancer Res. 2012 Mar 1;72(5):1070-80
pubmed: 22266112
Curr Top Microbiol Immunol. 2006;305:51-66
pubmed: 16724800
Lancet. 2010 Nov 20;376(9754):1741-50
pubmed: 20970847
Prostate. 2011 Jun 1;71(8):813-23
pubmed: 21456064
FASEB J. 1998 Sep;12(12):1063-73
pubmed: 9737710
Cancer Res. 2000 Mar 1;60(5):1306-11
pubmed: 10728691
Int J Mol Sci. 2020 Dec 05;21(23):
pubmed: 33291445
J Immunol. 2006 Nov 15;177(10):7303-11
pubmed: 17082649
Int J Cancer. 1996 Sep 27;68(1):34-8
pubmed: 8895537
Am J Obstet Gynecol. 1973 Mar 1;115(5):677-86
pubmed: 4739435
Annu Rev Biochem. 2008;77:289-312
pubmed: 18518822
Lancet Oncol. 2007 Oct;8(10):912-20
pubmed: 17881290
Gynecol Oncol. 2011 Aug;122(2):307-12
pubmed: 21616522
Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:42-58
pubmed: 28986092
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
J Lab Clin Med. 1993 Nov;122(5):518-23
pubmed: 8228569
Int J Cancer. 2017 Dec 1;141(11):2174-2186
pubmed: 28730615
Clin Breast Cancer. 2004 Feb;4(6):428-33
pubmed: 15023244
J Immunother. 2021 Feb-Mar 01;44(2):63-70
pubmed: 33443972
J Immunol. 2005 Aug 1;175(3):1483-90
pubmed: 16034085
Am J Obstet Gynecol. 1990 Jun;162(6):1633-4
pubmed: 2163194
Nat Rev Cancer. 2002 May;2(5):342-50
pubmed: 12044010
J Natl Cancer Inst. 1997 Oct 15;89(20):1516-23
pubmed: 9337348
Clin Immunol. 2010 Mar;134(3):277-88
pubmed: 19900843
J Immunol. 1995 Aug 1;155(3):1151-64
pubmed: 7636184
Immunobiology. 1991 Sep;183(1-2):79-87
pubmed: 1834546
Semin Oncol. 2004 Feb;31(1 Suppl 3):64-73
pubmed: 15052544
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
Arch Biochem Biophys. 1993 Jul;304(1):226-34
pubmed: 8323287
J Tongji Med Univ. 1991;11(4):235-9
pubmed: 1668016
J Immunol. 2002 Sep 1;169(5):2756-61
pubmed: 12193750
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Gynecol Oncol. 1991 Dec;43(3):275-80
pubmed: 1661264
Oncol Rep. 2003 Mar-Apr;10(2):309-13
pubmed: 12579264
Front Immunol. 2014 Mar 26;5:127
pubmed: 24723924